Clinical Trials · NCT06930625
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Debiopharm International SA
- Enrollment
- 119
- Start date
- Nov 2025
- Locations
- 73 sites, 21 countries
- Primary endpoint
- Double-blind Period: Percentage of Participants With IGF-1 ≤1x ULN